CN106421650A - Application of traditional Chinese medicinal composition in preparing medicines for treating senile fundus arteriosclerosis and fundus maculopathy - Google Patents

Application of traditional Chinese medicinal composition in preparing medicines for treating senile fundus arteriosclerosis and fundus maculopathy Download PDF

Info

Publication number
CN106421650A
CN106421650A CN201610956867.3A CN201610956867A CN106421650A CN 106421650 A CN106421650 A CN 106421650A CN 201610956867 A CN201610956867 A CN 201610956867A CN 106421650 A CN106421650 A CN 106421650A
Authority
CN
China
Prior art keywords
chinese medicine
radix
fundus
traditional chinese
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610956867.3A
Other languages
Chinese (zh)
Other versions
CN106421650B (en
Inventor
李卉
石丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEILIN PHARMACEUTICAL Co Ltd XI'AN
Original Assignee
BEILIN PHARMACEUTICAL Co Ltd XI'AN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEILIN PHARMACEUTICAL Co Ltd XI'AN filed Critical BEILIN PHARMACEUTICAL Co Ltd XI'AN
Priority to CN201610956867.3A priority Critical patent/CN106421650B/en
Publication of CN106421650A publication Critical patent/CN106421650A/en
Application granted granted Critical
Publication of CN106421650B publication Critical patent/CN106421650B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538—Schizonepeta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A61K36/638—Ligustrum, e.g. Chinese privet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to an application of a traditional Chinese medicinal composition in preparing medicines for treating senile fundus arteriosclerosis and fundus maculopathy, and belongs to the technical field of medicines. The applicant, through clinical researches and animal experiments on blood harmonizing and eyesight improving tablets, discovers that the traditional Chinese medicinal composition has a good therapeutic effect on the senile fundus arteriosclerosis in the clinical field; in a process of conducting pharmacological researches, the applicant, on the basis of the principle of adding and subtracting traditional Chinese medicines, adds radix cynanchi panicullati, herba schizonepetae and white atractylodes rhizome based on the prescription of the blood harmonizing and eyesight improving tablets, so that the therapeutic effect on the senile fundus arteriosclerosis is enhanced; the traditional Chinese medicinal composition can obviously reduce such indexes as TC, TG and the like and significantly increase HDL; and more importantly, the traditional Chinese medicinal composition has a significant difference with atorvastatin in an anti-inflammatory effect; therefore, the traditional Chinese medicinal composition has a good clinical application prospect.

Description

A kind of Chinese medicine composition is preparing the senile ocular fundus arteriosclerosiss for the treatment of and fundus flavimaculatus Purposes in pathological changes medicine
Technical field
The present invention relates to a kind of and blood improving eyesight Chinese medicine composition new application, and in particular to prepared by the Chinese medicine composition Senile ocular fundus arteriosclerosiss and the purposes in fundus flavimaculatus pathological changes medicine is treated, belongs to pharmaceutical technology field.
Background technology
Senile ocular fundus arteriosclerosiss are the common retinopathys of more than 50～60 years old old people, with advancing age, Sickness rate gradually rises.Advanced age causes tremulous pulse whole body system degeneration, Schilder, in ductus arteriosus wall middle level, fiber-like occurs And hyaline degeneration, small number of patients is also possible to relevant with inherited genetic factorss.Senile ocular fundus arteriosclerosiss are GAS One typical case's " signal ", the people with senile ocular fundus arteriosclerosiss, there is hardening systemic arterial blood vessel more.
Senile ocular fundus arteriosclerosiss are a kind of chronic senile Blood vessel pattern, are a kind of aging phenomenons of human body.Old Property arteriosclerotic retinopathy, is the non-inflammation degeneration and proliferative lesion performance on the retina of tremulous pulse.With Tremulous pulse wall thickening, change are elastic and hardening for principal character.The old people of 50～60 years old is generally betided, is to invade systemic arterial The degeneration of system and diffusivity arteriosclerosis.The urgency of the weight of retinopathy degree and development is delayed, the degree with whole body pathology Relevant with progress.The retinopathy that these systemic diseases cause develops to a certain extent, and visual function will be caused damage, and needs Positive remedy measures to be taken in time.
Although senile ocular fundus arteriosclerosiss weaken can mental and physical exertion, serious tissue is seldom caused to damage Wound, eye can no any symptom, but can be found that in inspection Fundus oculi artery generally attenuate, color thin out dimmed with reflective.Have When sexually revise as choroidal arteriosclerosises can make retina produce secondary, such as pigment disorder, glass-film wart, or even cause old Property degeneration of macula.Patient notes taking in high heat, the higher fatty acid, food of hypercholesterolemia class as far as possible less in diet at ordinary times；Eat vegetable more Dish, fruit；Smoking cessation limits wine, not eating and drinking too much at one meal；Happy mood is kept, is done more physical exercises.It is generally acknowledged that these methods are in certain journey The process of old ocular fundus arteriosclerosiss can be delayed on degree.If while with hypertension, hyperlipidemia and diabetes etc., can accelerate old The process of year property ocular fundus arteriosclerosiss, and senile ocular fundus arteriosclerosiss can also increase the Eye disease of above-mentioned disease in turn, So, the patient for suffering from hypertension, hyperlipidemia and diabetes wants active treatment, in order to avoid cause serious Eye disease and blind.
At present, the medicine for being clinically used for treating senile ocular fundus arteriosclerosiss mainly has (1) lipid regulating agent：Mainly lead to Cross reduction TC and LDL to alleviate the state of an illness, which represents medicine for Statins and bile acid binding resin class；(2) antioxidant：Mainly It is to resist oxygen free radicals in blood and ox-LDL to reach the purpose for treating senile ocular fundus arteriosclerosiss, representing medicine has general sieve Cloth examines (probucol) and vitamin E；(3) polyenoic fatty acids (PUFA)：It is divided into N-6 type polyenoic fatty acid and N-3 type polyenoid Fatty acid, on the one hand such medicine is by regulation blood fat, is on the other hand by suppression platelet aggregation, expansion of blood vessels, changes Kind microcirculation reaches the purpose for the treatment of；(4) mucopolysaccharide and polysaccharide：Such medicine can protect vascular endothelial cell, prevent blood The transfer of pipe smooth muscle cell and propagation, representing medicine has low molecular weight heparin and Heparan sulfate.Said medicine is old in treatment It is essentially all the degree for mitigating senile ocular fundus arteriosclerosiss by lipid-loweringing, antioxidation in terms of year property ocular fundus arteriosclerosiss, The development process of speckle cannot fundamentally be prevented it is therefore seen that, the medicine of the senile ocular fundus arteriosclerosiss of clinical treatment is still not Can be satisfactory, research and develop a kind of senile ocular fundus arteriosclerosiss medicine and still have important practical significance and economic valency Value.
Differentiation of tcm improves patient body function on the whole, accumulates in terms of senile ocular fundus arteriosclerosiss are treated Rich experience and theory, have reached preferable effect.It is the Chinese medicine preparation that produced by Forest of Steles in Xi'an Pharmaceutical with XUEMINGMU PIAN, Clinic cures mainly cooling blood for hemostasis, YIN nourishing blood stasis dispelling, nourishing the liver to improve visual acuity.For deficiency of YIN liver-yang hyperactivity, the retinal hemorrhage caused by thermal burn channels.Country Food and medicine Surveillance Authority in December, 2002 promulgates《National standard for traditional Chinese medicines compilation ophthalmology department of otorhinolaryngology department of dermatologry fascicle》 " and XUEMINGMU PIAN " under WS-10062 (ZD-0062) -2002 discloses its prescription and preparation method.
The Chinese patent publication of on October 29th, 2003 discloses " a kind of Chinese medicine for treating optical fundus hemorrhage and its preparation side Method ", the patent application of Publication No. CN1451422A, the weight proportion of each herbal medicine raw material of the composition invention Chinese patent medicine For：Pollen Typhae 65-80 part, Radix Salviae Miltiorrhizae 65-80 part, Radix Rehmanniae 50-70 part, Herba Ecliptae 50-70 part, Flos Chrysanthemi 40-60 part, charcoal Radix Scutellariae 35-50 Part, Semen Cassiae 35-50 part, Semen Plantaginiss 35-50 part, Fructus Leonuri 35-50 part, Fructus Ligustri Lucidi 35-50 part, Spica Prunellae 35-50 part, Radix Gentianae 35-50 part, Radix Curcumae 20-40 part, Herba Equiseti Hiemalises' 35-50 part, Radix Paeoniae Rubra 20-40 part, Cortex Moutan 20-40 part, Fructus Crataegi 20-40 part, Radix Angelicae Sinensis 20- 40 parts, Rhizoma Chuanxiong 5-15 part.
Chinese invention patent CN102319398B discloses a kind of and XUEMINGMU PIAN improvement prescription, and its prescription is consisted of： Pollen Typhae 75g, Radix Salviae Miltiorrhizae 75g, Radix Rehmanniae 60g, Herba Ecliptae 40g, Flos Chrysanthemi 50g, charcoal Radix Scutellariae 45g, Semen Cassiae 45g, Semen Plantaginiss 45g, motherwort Sub- 45g, Fructus Ligustri Lucidi 45g, Spica Prunellae 45g, Radix Gentianae 45g, Radix Curcumae 15g, Herba Equiseties Hiemalis 30g, Radix Paeoniae Rubra 30g, Cortex Moutan 30g, Fructus Crataegi 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, its after the consumption for increasing Rhizoma Chuanxiong is while reduce the consumption of Herba Ecliptae, Radix Curcumae and Herba Equiseties Hiemalis, find for Deficiency of YIN liver-yang hyperactivity, the enhancing evident in efficacy of the retinal hemorrhage caused by thermal burn channels, and without any side effects.
Chinese invention patent CN102319400B discloses a kind of and XUEMINGMU PIAN new preparation technology, its original and On the basis of XUEMINGMU PIAN technique, find to make the water extraction in its technique after 6 times amount, 60% ethanol extracts into, the carrying of effective ingredient The rate of taking is significantly improved, and its clinical pharrnacokinetics experiment effect is significantly improved, good stability, and safe without toxic side effect.
Content of the invention
Applicant to and the clinical research and zoopery of XUEMINGMU PIAN in, find which for senile eye clinically Bottom arteriosclerosis with good therapeutic effect, which results in the concern of applicant, in materia medica research process, applicant By Chinese medicine add and subtract taste principle to and the prescription of XUEMINGMU PIAN have made intensive studies, develop one kind and be specially adapted for old eye Bottom arteriosclerosis and the Chinese medicine composition of fundus flavimaculatus lesions treatment, propose the present invention based on this spy.
The above-mentioned technique effect of the present invention is achieved through the following technical solutions：
A kind of purposes of Chinese medicine composition in the senile ocular fundus arteriosclerosiss of preparation treatment and fundus flavimaculatus pathological changes medicine, The prescription of wherein described Chinese medicine composition is consisted of：Pollen Typhae 75g, Radix Salviae Miltiorrhizae 75g, Radix Rehmanniae 60g, Herba Ecliptae 40g, Flos Chrysanthemi 50g, charcoal Radix Scutellariae 45g, Semen Cassiae 45g, Semen Plantaginiss 45g, Fructus Leonuri 45g, Fructus Ligustri Lucidi 45g, Spica Prunellae 45g, Radix Gentianae 45g, Radix Curcumae 15g, wood Crafty 30g, Radix Paeoniae Rubra 30g, Cortex Moutan 30g, Fructus Crataegi 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g.
On the basis of above-mentioned prescription, after adding Radix Cynanchi Paniculati, Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae, which is controlled to senile ocular fundus arteriosclerosiss Therapeutic effect is significantly increased, therapeutic effect expection substantially beyond those skilled in the art.Applicant is according to old age after prescription The enhancing of the therapeutic effect of property ocular fundus arteriosclerosiss has been carried out to prescription further preferably, it is preferable that described Chinese medicine composition Also containing Radix Cynanchi Paniculati 30g, Herba Schizonepetae 25g and Rhizoma Atractylodis Macrocephalae 20g.Or preferably, described Chinese medicine composition also containing Radix Cynanchi Paniculati 15g, Herba Schizonepetae 15g and Rhizoma Atractylodis Macrocephalae 20g.
In medicinal usage described above, the pharmaceutical preparation comprising Chinese medicine composition is its oral formulations, described Oral formulations are its tablet, capsule, granule, syrup, and the one kind in drop pill is preferably its tablet.The Chinese medicine composition The preparation method of the pharmaceutical preparation of thing all can be prepared according to preparation technology well-known to those skilled in the art.Preferably, The preparation method of the pharmaceutical preparation of the Chinese medicine composition comprises the steps：
Accurately claim recipe quantity Chinese crude drug, Flos Chrysanthemi, charcoal Radix Scutellariae, half measure Semen Plantaginiss, half amount Pollen Typhae, and mixed powder is broken into fine powder, standby With；Remaining Semen Plantaginiss, Pollen Typhae and remaining each taste add 60% ethanol to soak 30 minutes, and reflux, extract, is secondary, 2 hours every time, and first Secondary plus 60% ethanol, 6 times amount, second plus 60% ethanol, 6 times amount, merge extracting solution twice, filtration；Filtrate reduced in volume time control Vacuum processed is -0.08MPa, temperature is 80 DEG C, to be concentrated into the thick paste that temperature is that when 60 DEG C, relative density is 1.35～1.39, plus Enter above-mentioned fine powder mix homogeneously, 60 DEG C dry, and fine powder is ground into, and each dosage form proper auxiliary materials are added, by each dosage form common process system Piece agent, capsule, granule or drop pill.
The embodiment of the present invention 9 finds, Serum bichemisbry result shows, compared with Normal group, model group HDL significantly drops Low, other indexs are significantly raised, and all have significant difference, show modeling success；Compared with model group, traditional Chinese medicine composition for treating group Significantly raise with atorvastatin group HDL, all other indexs are significantly reduced, index no significant difference between two groups, in showing The effect for reducing fat of drug composition is suitable with atorvastatin；Compare with model group, traditional Chinese medicine composition for treating group MM-9 and VCAM-1 All significantly reduce, have significant difference (P ＜ 0.05), also there is compared with atorvastatin group the difference of significance, in showing Drug composition treatment group is better than atorvastatin in antiphlogistic effects.
In purposes of the present invention, if described senile ocular fundus arteriosclerosiss patient is while with fundus flavimaculatus disease Become, Chinese medicine composition of the present invention can also substantially reduce fundus flavimaculatus lesion degree, therefore for senile ocular fundus arteriosclerosiss While there is positive therapeutic effect with the patient of fundus flavimaculatus pathological changes.
Chinese medicine composition of the present invention have the advantage that compared with prior art for：
1) and XUEMINGMU PIAN is clinically to apply the Chinese medicine preparation of the various retinal hemorrhage for the treatment of for many years, applicant is in reality Test middle find which has an effect for treating senile ocular fundus arteriosclerosiss and fundus flavimaculatus pathological changes well, and it is found by the applicant that its For senile ocular fundus arteriosclerosiss therapeutic effect with and XUEMINGMU PIAN in prescription Chinese crude drug very big, the Chinese medicine with magnitude relation The consumption of material changes, and which is remarkably decreased for the therapeutic effect of senile ocular fundus arteriosclerosiss.
2) with XUEMINGMU PIAN prescription on the basis of add Radix Cynanchi Paniculati, which is hard for senile Fundus oculi artery after Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae The therapeutic effect of change is significantly increased, and this shows that the three kinds of Chinese crude drugs for adding generate the senile Fundus oculi artery for the treatment of with original prescription Synergy in terms of hardening, preferably finds through prescription, when addition Radix Cynanchi Paniculati 30g, Herba Schizonepetae 25g and Rhizoma Atractylodis Macrocephalae 20g, or Xu are long When minister in ancient times 15g, Herba Schizonepetae 15g and Rhizoma Atractylodis Macrocephalae 20g, its therapeutic effect is the most excellent.
3) clinically apply for many years with XUEMINGMU PIAN, have good clinical practice experience, its drug safety, user Just, bring glad tidings to countless patients, present invention discover that the treatment new application with XUEMINGMU PIAN, greatly can extend and blood improving eyesight The Clinical practice scope of piece, and drug safety height.
Specific embodiment
The present invention being further described below by way of specific embodiment, but the embodiment limits this never in any form Bright scope of patent protection.
1 present invention of embodiment is used for treating the Chinese medicine composition of senile ocular fundus arteriosclerosiss
A kind of purposes of Chinese medicine composition in the senile ocular fundus arteriosclerosiss of preparation treatment and fundus flavimaculatus pathological changes medicine, The prescription of wherein described Chinese medicine composition is consisted of：Pollen Typhae 75g, Radix Salviae Miltiorrhizae 75g, Radix Rehmanniae 60g, Herba Ecliptae 40g, Flos Chrysanthemi 50g, charcoal Radix Scutellariae 45g, Semen Cassiae 45g, Semen Plantaginiss 45g, Fructus Leonuri 45g, Fructus Ligustri Lucidi 45g, Spica Prunellae 45g, Radix Gentianae 45g, Radix Curcumae 15g, wood Crafty 30g, Radix Paeoniae Rubra 30g, Cortex Moutan 30g, Fructus Crataegi 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g.
Preparation technology：Accurately claim recipe quantity Chinese crude drug, Flos Chrysanthemi, charcoal Radix Scutellariae, half amount Semen Plantaginiss, half amount Pollen Typhae, co-grinding Become fine powder, standby；Remaining Semen Plantaginiss, Pollen Typhae and remaining each taste add 60% ethanol to soak 30 minutes, and reflux, extract, is secondary, and every time 2 Hour, add 60% ethanol, 6 times amount for the first time, second plus 60% ethanol, 6 times amount, merge extracting solution twice, filtration；Filtrate decompression During concentration control vacuum be -0.08MPa, temperature be 80 DEG C, be concentrated into temperature for 60 DEG C when relative density be 1.35～1.39 Thick paste, add above-mentioned fine powder mix homogeneously, 60 DEG C of drying, be ground into fine powder, add each dosage form proper auxiliary materials, normal by each dosage form Rule technique makes tablet, capsule, granule or drop pill.
2 present invention of embodiment is used for treating the Chinese medicine composition of senile ocular fundus arteriosclerosiss
A kind of purposes of Chinese medicine composition in the senile ocular fundus arteriosclerosiss of preparation treatment and fundus flavimaculatus pathological changes medicine, The prescription of wherein described Chinese medicine composition is consisted of：Pollen Typhae 75g, Radix Salviae Miltiorrhizae 75g, Radix Rehmanniae 60g, Herba Ecliptae 40g, Flos Chrysanthemi 50g, charcoal Radix Scutellariae 45g, Semen Cassiae 45g, Semen Plantaginiss 45g, Fructus Leonuri 45g, Fructus Ligustri Lucidi 45g, Spica Prunellae 45g, Radix Gentianae 45g, Radix Curcumae 15g, wood Crafty 30g, Radix Paeoniae Rubra 30g, Cortex Moutan 30g, Fructus Crataegi 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g, Radix Cynanchi Paniculati 30g, Herba Schizonepetae 25g and Rhizoma Atractylodis Macrocephalae 20g.
Preparation technology is with embodiment 1.
3 present invention of embodiment is used for treating the Chinese medicine composition of senile ocular fundus arteriosclerosiss
The pharmaceutical preparation of Chinese medicine composition is prepared according to following prescription ratio respectively, wherein except Radix Cynanchi Paniculati, Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae Consumption have outside difference, remaining prescription ratio is all with embodiment 2.
The consumption of Radix Cynanchi Paniculati, Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae in 1 embodiment 3-6 pharmaceutical preparation of table
Prescription Radix Cynanchi Paniculati (g) Herba Schizonepetae (g) The Rhizoma Atractylodis Macrocephalae (g)
Embodiment 3 15 15 20
Embodiment 4 30 20 20
Embodiment 5 45 25 20
Embodiment 6 30 20 30
Embodiment 7 45 25 30
Embodiment 8 15 20 30
Therapeutic effect of the Chinese medicine composition of the present invention of embodiment 9 to senile ocular fundus arteriosclerosiss new zealand rabbit
1. experimental technique
80 healthy new zealand white rabbits are taken, body weight is 2.5～3.0kg, to be randomly divided into Normal group, model comparison Totally 10 groups of the basic, normal, high dosage group of group, Chinese medicine composition, atorvastatin group, per organizing 8, all male, all animals notes Number pen traces Arabic numerals to distinguish individuality in left ear.The high fat breast of the leading gavage of animal 1 month, the detection of ear edge arterial blood extracting is dynamic After thing TG, TC are raised, pentobarbital sodium 30mg/kg auricular vein injecting anesthetic, cervical region is rejected by hair, sterilization, surgical exposure are moved Thing left common carotid 2.5cm or so, closes blood vessel proximal part and distal end with bulldog clamp successively folder, and between two ends, artery-sparing is long Spending for 2cm or so, 1% concentration sodium laurate 0.1ml is drawn with insulin injection syringe and inject blood vessel, unclamps distal end blood after 5min Pipe clamp, unclamps proximal part again after cotton balls hemostasis by compression, sews up a wound, and puts back to rearging cage after disinfecting.Postoperative muscle for three days on end After injecting the sterilization of 800,000 units of Penicillin, start gastric infusion, administration phase is limited to 2 months, is administered once daily, while continuing daily The high fat breast of continuous gavage.
5. experimental result
Ear edge arterial blood extracting 4ml after two months is administered, centrifuging and taking serum, using automatic clinical chemistry analyzer detection blood Clear TG (blood fat), TC (cholesterol), HDL (high density lipoprotein), LDL (low density lipoprotein, LDL), are detected using euzymelinked immunosorbent assay (ELISA) MM-9 (Matrix Metalloproteinase-9), VCAM-1 (vascular cell adhesion melecule)；Animal sacrificed by exsanguination, takes left side neck and always moves Arteries and veins does SABC, the senile ocular fundus arteriosclerosiss degree of detection common carotid artery.
2 therapeutic effect of the different treatment groups to senile ocular fundus arteriosclerosiss new zealand rabbit of table
Compared with Normal group,##P<0.01；*Compared with 1 group of Chinese medicine,*P<0.05, compared with atorvastatin group,▼p <0.05.
From table 2, Serum bichemisbry result shows, compared with Normal group, model group HDL is significantly reduced, other Index is significantly raised, and all has significant difference, shows modeling success；Compared with model group, traditional Chinese medicine composition for treating group and atropic Cut down statin group HDL significantly to raise, all other indexs are significantly reduced, between two groups, index no significant difference, shows Chinese medicine composition The effect for reducing fat of thing is suitable with atorvastatin；Compare with model group, traditional Chinese medicine composition for treating group MM-9 and VCAM-1 are all notable Reduce, have significant difference (P ＜ 0.05), also there is compared with atorvastatin group the difference of significance, show Chinese medicine composition Thing treatment group is better than atorvastatin (being shown in Table 2) in antiphlogistic effects.
Concrete outcome is as follows：
1) TG, TC, LDL of 1 group for the treatment of group of Chinese medicine is significantly reduced compared with model group, HDL notable liter compared with model group Height, with significant difference, this shows that 1 group of Chinese medicine (i.e. with the prescription of XUEMINGMU PIAN) can be used as senile ocular fundus arteriosclerosiss Medicine is used.
2) 2 group of -8 group TG, TC of Chinese medicine, significantly reduce compared with 1 group of LDL and Chinese medicine, notable rising compared with 1 group of HDL and Chinese medicine, With significant difference, this is treating senile eye after showing to be added into Radix Cynanchi Paniculati, Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae on the basis of 1 group of Chinese medicine Significant synergism is achieved in terms of the arteriosclerosis of bottom and original prescription drug between, wherein especially with 2 groups of Chinese medicine and Chinese medicine 3 Group is optimal, is two optimal embodiments of the present invention.
3) 2 group of -8 group of Chinese medicine is in MM-9 content and VCAM-1 content and atorvastatin group compared with atorvastatin group Compare and significantly reduce, this shows in prescription, add Radix Cynanchi Paniculati, Herba Schizonepetae and the Rhizoma Atractylodis Macrocephalae to cause the antiphlogistic effects of Chinese medicine composition notable Strengthen, can effectively prevent speckle from coming off for senile ocular fundus arteriosclerosiss so that the drug safety of patient increases.
Meanwhile, histopathology result display model group animal blood vessels endothelium defect, proliferation of fibrous tissue, subendothelial visible Angiogenesiss, the visible endothelial injury of atorvastatin group, subendothelial have foam cell, visible a large amount of cavitys, smooth muscle in endochylema Hypertrophy, each treatment group of Chinese medicine composition has no angiogenesiss and proliferation of smooth muscle, and rarely seen subendothelial have the foam cell being dispersed in, table The inhibition that bright Chinese medicine composition develops to senile ocular fundus arteriosclerosiss is better than atorvastatin.
In sum, it is believed that Chinese medicine composition is mitigating senile ocular fundus arteriosclerosiss inflammatory reaction, suppression speckle Atorvastatin is better than in terms of development, can effectively treat senile ocular fundus arteriosclerosiss.

Claims (9)

1. purposes of a kind of Chinese medicine composition in the senile ocular fundus arteriosclerosiss medicine for the treatment of is prepared, wherein described Chinese medicine group The prescription of compound is consisted of：Pollen Typhae 75g, Radix Salviae Miltiorrhizae 75g, Radix Rehmanniae 60g, Herba Ecliptae 40g, Flos Chrysanthemi 50g, charcoal Radix Scutellariae 45g, Semen Cassiae 45g, Semen Plantaginiss 45g, Fructus Leonuri 45g, Fructus Ligustri Lucidi 45g, Spica Prunellae 45g, Radix Gentianae 45g, Radix Curcumae 15g, Herba Equiseties Hiemalis 30g, Radix Paeoniae Rubra 30g, Cortex Moutan 30g, Fructus Crataegi 30g, Radix Angelicae Sinensis 30g, Rhizoma Chuanxiong 60g.
2. purposes according to claim 1, it is characterised in that described Chinese medicine composition also include Radix Cynanchi Paniculati, Herba Schizonepetae and The Rhizoma Atractylodis Macrocephalae.
3. purposes according to claim 1, it is characterised in that also include Xu in the prescription composition of described Chinese medicine composition Long minister in ancient times 30g, Herba Schizonepetae 25g and Rhizoma Atractylodis Macrocephalae 20g.
4. purposes according to claim 1, it is characterised in that also include Xu in the prescription composition of described Chinese medicine composition Long minister in ancient times 15g, Herba Schizonepetae 15g and Rhizoma Atractylodis Macrocephalae 20g.
5. according to the arbitrary described purposes of claim 1-4, it is characterised in that the pharmaceutical preparation comprising Chinese medicine composition is Its oral formulations.
6. purposes according to claim 5, it is characterised in that described oral formulations be Agent, syrup, the one kind in drop pill.
7. purposes according to claim 6, it is characterised in that described oral formulations be.
8. purposes according to claim 1, it is characterised in that the preparation method bag of the pharmaceutical preparation of the Chinese medicine composition Include following steps：
Accurately claim recipe quantity Chinese crude drug, Flos Chrysanthemi, charcoal Radix Scutellariae, half measure Semen Plantaginiss, half amount Pollen Typhae, and mixed powder is broken into fine powder, standby；Surplus Remaining Semen Plantaginiss, Pollen Typhae and remaining each taste add 60% ethanol to soak 30 minutes, and reflux, extract, is secondary, 2 hours every time, add for the first time 60% ethanol, 6 times amount, second plus 60% ethanol, 6 times amount, merge extracting solution twice, filtration；Control during filtrate reduced in volume true Reciprocal of duty cycle is -0.08MPa, temperature is 80 DEG C, to be concentrated into the thick paste that temperature is that when 60 DEG C, relative density is 1.35～1.39, in addition Fine powder mix homogeneously is stated, and 60 DEG C dry, and fine powder is ground into, and each dosage form proper auxiliary materials are added, piece is made by each dosage form common process Agent, capsule, granule or drop pill.
9. purposes according to claim 1, it is characterised in that described senile ocular fundus arteriosclerosiss patient and meanwhile with Fundus flavimaculatus pathological changes.
CN201610956867.3A 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation Active CN106421650B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610956867.3A CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610956867.3A CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Publications (2)

Publication Number Publication Date
CN106421650A true CN106421650A (en) 2017-02-22
CN106421650B CN106421650B (en) 2019-08-13

Family

ID=58180190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610956867.3A Active CN106421650B (en) 2016-10-26 2016-10-26 A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation

Country Status (1)

Country Link
CN (1) CN106421650B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255344A (en) * 1998-11-30 2000-06-07 万前烈 Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes
CN1283477A (en) * 2000-07-13 2001-02-14 郭连川 'Yanming' capsules for clearing eyes
CN102319398A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 A kind of and the blood Chinese medicine composition and preparation method thereof that makes eye bright
CN102319400A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 Traditional Chinese drug composition for blood cooling, hemostasis, yin nourishing, blood stasis dissipating, liver nourishing and eyesight improving, and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1255344A (en) * 1998-11-30 2000-06-07 万前烈 Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes
CN1283477A (en) * 2000-07-13 2001-02-14 郭连川 'Yanming' capsules for clearing eyes
CN102319398A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 A kind of and the blood Chinese medicine composition and preparation method thereof that makes eye bright
CN102319400A (en) * 2011-09-26 2012-01-18 西安碑林药业股份有限公司 Traditional Chinese drug composition for blood cooling, hemostasis, yin nourishing, blood stasis dissipating, liver nourishing and eyesight improving, and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吕小利等: "糖尿病性视网膜病变动脉硬化程度与中药治疗介入时机的相关性研究", 《浙江中西医结合杂志》 *

Also Published As

Publication number Publication date
CN106421650B (en) 2019-08-13

Similar Documents

Publication Publication Date Title
CN104208302A (en) Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof
CN103301412A (en) Traditional Chinese medicine composition for treating alcoholic liver
CN103099959A (en) Traditional Chinese medicine preparation for treating ulcerative colitis and preparation method thereof
CN102205107A (en) Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof
CN104958607A (en) Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof
CN104206594A (en) Herba Taxilli health-care tea capable of lowering blood pressure and blood lipid and preparation method thereof
CN104758806A (en) Decocted extract for treating coronary heart disease and preparation method thereof
CN103749824B (en) A kind of Herb Gynostemmae Pentaphylli blood sugar lowering blood pressure depressing health tea and preparation method thereof
CN1558768A (en) A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof
CN105250813A (en) Chinese herb composition for treating jaundice
CN104398980A (en) Traditional Chinese medicine preparation for treating apoplectic hemiplegia and preparation method of traditional Chinese medicine preparation
CN105012873A (en) Health-care blood-fat-lowering evening primrose oral liquid and preparation method thereof
CN102949659B (en) Traditional Chinese medicine composition for treating hepatitis B
CN105687788A (en) Pharmaceutical composition capable of softening blood vessels and application thereof
CN105943705A (en) Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof
CN105056103A (en) Steamed buns with assistant effect of reducing blood fat and cholesterol and processing method of steamed buns
CN105343593A (en) Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid
CN104706839A (en) Traditional Chinese medicine preparation for treating rheumatic arthritis
CN103656226A (en) Compound medicine for treating sicca syndrome
CN106421650B (en) A kind of Chinese medicine composition treats the purposes in senile ocular fundus arteriosclerosis and fundus flavimaculatus lesion drug in preparation
CN105497262A (en) Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome
CN104857363A (en) Combined Chinese herbal preparation for reducing blood fat and preparation method thereof
CN103549072A (en) Vital energy-benefiting brain-boosting tea and preparation method thereof
CN103285360B (en) Traditional Chinese medicinal preparation for treating thromboangiitis obliterans, and preparation method thereof
CN101884735B (en) Medicine for treating dyslipidemia and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant